
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is a promising company with a unique technology platform for treating peanut allergies. Its Viaskin Peanut patch has shown promising results in clinical trials and could potentially change the landscape of peanut allergy treatment. Despite some potential financial and commercial risks, we believe DBVT is well-positioned to become a leader in the immunotherapy space with its differentiated approach and potential for future growth in other common allergens. We maintain a positive outlook and reiterate our Market Outperform rating and increased price target.
Bears say
DBV Technologies is facing multiple challenges and uncertainties, including the delay in FDA approval for Viaskin Peanut and the need for additional safety studies. This could impact the company's financial performance as it continues to invest in its pipeline and prepare for multiple BLA submissions. Furthermore, DBVT's reliance on a single product candidate and lack of diversification in its pipeline may make it a risky investment.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares